1. Home
  2. RA vs EOLS Comparison

RA vs EOLS Comparison

Compare RA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RA
  • EOLS
  • Stock Information
  • Founded
  • RA 2016
  • EOLS 2012
  • Country
  • RA United States
  • EOLS United States
  • Employees
  • RA N/A
  • EOLS N/A
  • Industry
  • RA Investment Managers
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • RA Finance
  • EOLS Health Care
  • Exchange
  • RA Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • RA 741.9M
  • EOLS 702.2M
  • IPO Year
  • RA N/A
  • EOLS 2018
  • Fundamental
  • Price
  • RA $13.38
  • EOLS $10.51
  • Analyst Decision
  • RA
  • EOLS Strong Buy
  • Analyst Count
  • RA 0
  • EOLS 6
  • Target Price
  • RA N/A
  • EOLS $22.60
  • AVG Volume (30 Days)
  • RA 280.8K
  • EOLS 695.8K
  • Earning Date
  • RA 01-01-0001
  • EOLS 03-06-2025
  • Dividend Yield
  • RA 14.73%
  • EOLS N/A
  • EPS Growth
  • RA N/A
  • EOLS N/A
  • EPS
  • RA N/A
  • EOLS N/A
  • Revenue
  • RA N/A
  • EOLS $248,326,000.00
  • Revenue This Year
  • RA N/A
  • EOLS $33.43
  • Revenue Next Year
  • RA N/A
  • EOLS $32.44
  • P/E Ratio
  • RA N/A
  • EOLS N/A
  • Revenue Growth
  • RA N/A
  • EOLS 34.42
  • 52 Week Low
  • RA $11.89
  • EOLS $9.25
  • 52 Week High
  • RA $17.32
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • RA 53.26
  • EOLS 42.77
  • Support Level
  • RA $13.22
  • EOLS $9.25
  • Resistance Level
  • RA $13.34
  • EOLS $11.66
  • Average True Range (ATR)
  • RA 0.11
  • EOLS 0.55
  • MACD
  • RA 0.00
  • EOLS 0.06
  • Stochastic Oscillator
  • RA 74.42
  • EOLS 52.28

About RA Brookfield Real Assets Income Fund Inc.

Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities (collectively, Real Asset Companies and Issuers). The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: